Windlas Biotech Share Price Today

Windlas Biotech appoints two independent directors; Vivek Dhariwal resigns

Windlas Biotech appointed Aashish Mehra and Soni Saran Singh as independent directors on October 12, 2026. Vivek Dhariwal resigned as Independent Director and Board Chairman citing personal reasons. New appointments are for five-year terms subject to shareholder approval. Mehra has over two decades of experience in pharma and life sciences strategy.

Windlas Biotech Q1FY27 revenue hits record ₹248 crore, up 18%

Windlas Biotech achieved record Q1FY27 revenue of ₹248 crore, driven by 29% growth in its CDMO vertical. The company returned capital via a ₹47 crore buyback and a ₹6.30 dividend. Plant 6 commercialization is targeted for H1FY27, supporting future capacity needs.

Windlas Biotech Q1 Results: Revenue rises to 2.5B rupees, EBITDA margin contracts to 10.75% YoY

Windlas Biotech's Q1 consolidated results showed revenue growth to 2.5B rupees from 2.1B rupees year-on-year, while net profit remained flat at 177M rupees. EBITDA rose marginally to 267M rupees from 265M rupees, but EBITDA margin contracted notably to 10.75% from 12.60% YoY. The results indicate top-line expansion accompanied by margin pressure during the quarter.

Windlas Biotech schedules Q1FY27 earnings call for Aug 11

Windlas Biotech Limited has announced a conference call scheduled for August 11, 2026, at 11:30 AM IST. The session aims to discuss the financial results for the quarter ended June 30, 2026, with participation from key executives including Hitesh Windlass and Komal Gupta.

Windlas Biotech approves ₹6.30 dividend, reappoints directors

Windlas Biotech Limited concluded its 25th AGM with unanimous shareholder approval for a ₹6.30 per share final dividend for FY26. The meeting also saw the reappointment of Managing Director Hitesh Windlass and Director Prachi Jain Windlass, along with the appointment of Dr. Tarashree Singhal as an Independent Director. With a 71.39% voting turnout, all six resolutions, including the adoption of audited financial statements, passed without dissent. The process was scrutinized by Sandeep Joshi & Associates under SEBI Listing Regulations.

Windlas Biotech hosting analyst meet on 14 Jul 2026

Windlas Biotech has scheduled a virtual meeting for analysts and institutional investors on July 14, 2026, at 3:00 PM IST under SEBI regulations. The company stated that discussions will rely on publicly available documents and no unpublished price sensitive information will be disclosed.